Bristol-Myers Squibb (BMY) Reports Positive Camzyos Trial, Partners with Microsoft on AI Lung Cancer Detection

Bristol-Myers Squibb announced positive Phase 3 trial results for its heart drug Camzyos and a new AI collaboration with Microsoft on January 24, 2026. The developments signal strategic moves to bolster its cardiovascular and oncology portfolios. The SCOUT-HCM trial showed Camzyos was effective in adolescents with a specific heart condition. Separately, the partnership aims to use AI to improve early lung cancer detection within U.S. healthcare systems, targeting underserved communities.